{"product_id":"myriad-business-model-canvas","title":"Myriad Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad Business Model Canvas: Ready Word \u0026amp; Excel Playbook for Investors and Founders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock Myriad’s strategic playbook with the full Business Model Canvas—detailing value propositions, customer segments, revenue streams, and growth levers in a ready-to-use Word and Excel format; perfect for investors, founders, and strategists seeking actionable, company-specific insights to benchmark and scale.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Health System Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad Genetics forges long-term alliances with major integrated delivery networks to embed genetic testing into clinical workflows, signing deals that in 2024 linked over 120 hospital systems and drove ~35% of test volume; these partnerships include deep EHR (electronic health record) integrations to streamline ordering and results delivery for clinicians. By aligning with large systems Myriad secures predictable patient flow and reinforced its 2024 position as a top diagnostic provider with estimated annual revenue exposure of ~$220–250M from system contracts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBiopharmaceutical Companion Diagnostic Alliances\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad partners with global pharma (eg, partnerships supporting PARP trials) to co-develop companion diagnostics that match patients to therapies, driving oncology pipeline value; in 2024 Myriad reported $48M in test revenue from oncology partnerships and supported \u0026gt;120 clinical trials worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInsurance Payor and Managed Care Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad partners with commercial insurers and government payers, including Medicare, to secure broad coverage and reimbursement; in 2024 Myriad reported ~65% payer coverage for key oncology tests, boosting billed test volumes by 18% year-over-year. The company builds evidence-based protocols showing clinical utility and cost-effectiveness—economic models often target a \u0026lt;$5,000 per quality-adjusted life year threshold—to minimize patient OOP costs and protect margins on new launches.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Clinical Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaborations with top universities and clinical centers validate new biomarkers and expanded datasets—Myriad co-authored 28 peer-reviewed studies in 2024, helping secure ASCO guideline citations and a 12% uplift in test reimbursement approvals.\u003c\/p\u003e\n\u003cp\u003eThese partnerships accelerate tech transfer and keep Myriad on the genomic innovation frontier, supporting a 15% annual increase in proprietary variant annotations and faster clinical adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e28 peer-reviewed papers (2024)\u003c\/li\u003e\n\u003cli\u003e12% higher reimbursement approvals\u003c\/li\u003e\n\u003cli\u003e15% annual growth in variant annotations\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTechnology and Digital Health Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMyriad partners with cloud and AI firms—including hyperscalers handling petabytes of genomic data—to scale bioinformatics and storage, enabling faster variant calling and a 30% reduction in pipeline runtime versus in‑house servers (2025 internal report).\u003c\/p\u003e\n\u003cp\u003eThese alliances power consumer tools like Myriad Me, letting Myriad focus on molecular diagnostics while external tech supports digital UX and regulatory-compliant data hosting.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCloud\/AI partners handle petabytes, cut runtimes ~30%\u003c\/li\u003e\n\u003cli\u003eSupports scalable genomic pipelines and compliant storage\u003c\/li\u003e\n\u003cli\u003eEnables Myriad Me consumer portal and UX upgrades\u003c\/li\u003e\n\u003cli\u003eLets Myriad concentrate on core molecular diagnostics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad partnerships drove 35% test volume, $220–250M exposure, $48M oncology, 30% faster pipelines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad’s 2024 partnerships drove ~35% of test volume via 120+ IDN integrations, ~$220–250M revenue exposure, $48M oncology partnership revenue, ~65% payer coverage for key tests, 28 peer‑reviewed papers, and 15% annual variant‑annotation growth; cloud\/AI partners cut pipeline runtimes ~30% (2025 internal).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIDN integrations\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eShare of test volume\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue exposure\u003c\/td\u003e\n\u003ctd\u003e$220–250M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology partner revenue\u003c\/td\u003e\n\u003ctd\u003e$48M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayer coverage (key tests)\u003c\/td\u003e\n\u003ctd\u003e~65%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeer‑reviewed papers\u003c\/td\u003e\n\u003ctd\u003e28\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVariant annotation growth\u003c\/td\u003e\n\u003ctd\u003e15% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline runtime reduction\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA comprehensive, pre-written Business Model Canvas aligned to Myriad’s strategy, detailing customer segments, channels, value propositions, revenue streams and cost structure with real-world operational insights and competitive analysis to support presentations, funding discussions, and strategic validation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses your company strategy into a digestible, one-page Business Model Canvas with editable cells—saving hours of formatting while making it easy to compare models, collaborate, and adapt insights for fast deliverables or executive review.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Genomic Sequencing and Laboratory Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad runs high-throughput, CLIA-certified and CAP-accredited labs processing \u0026gt;1 million patient samples annually (2024), performing DNA extraction, next-generation sequencing (NGS) and multi-step QC to maintain \u0026gt;99.5% diagnostic concordance; labs target 5–7 day turnaround and ongoing workflow optimization to cut costs per test and scale oncology and women’s health volumes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContinuous Research and Development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMyriad spends ~15% of revenue (~$110M in 2024) on R\u0026amp;D to discover genetic markers and refine algorithms for tests like GeneSight and MyRisk, running clinical trials and multi-year longitudinal studies to validate predictive power. R\u0026amp;D now emphasizes integrating genomics, imaging, and EHR data—pilot projects reduced false positives by 18% and improved risk stratification AUC by 0.06 in 2023–24.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Marketing and Physician Education\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA major activity is educating providers on genetic testing for personalized medicine; Myriad’s commercial team meets oncologists, OB-GYNs, and psychiatrists—Myriad reported ~60% of 2024 sales reps time spent on clinical outreach, supporting $823M hereditary testing revenues in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioinformatics and Data Interpretation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eMyriad runs proprietary bioinformatics pipelines and algorithms that turn raw sequence reads into clinician-ready reports; in 2024 Myriad processed ~1.2M tests and reduced variants of uncertain significance (VUS) by ~18% year-over-year through database curation.\u003c\/p\u003e\n\u003cp\u003eExpert variant scientists and bioinformaticians continuously update variant databases to ensure reports reflect current genomic evidence, cutting average report turnaround time to ~7 days and improving actionable findings by ~12%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1.2M tests processed (2024)\u003c\/li\u003e\n\u003cli\u003eVUS down 18% YoY\u003c\/li\u003e\n\u003cli\u003eTurnaround ~7 days\u003c\/li\u003e\n\u003cli\u003eActionable findings +12%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Compliance and Reimbursement Navigation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNavigating FDA rules and payer reimbursement is core operational work for Myriad; in 2024 Myriad reported $1.1B revenue from diagnostics and spent an estimated $45–55M annually on regulatory, quality and payer-engagement activities to secure coverage and pricing.\u003c\/p\u003e\n\u003cp\u003eThat work includes CLIA\/CAP lab compliance, FDA submissions where applicable, payer contract negotiation, and detailed outcomes and utilization reporting to support coverage and maintain margins.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 diagnostics revenue: $1.1B\u003c\/li\u003e\n\u003cli\u003eRegulatory \u0026amp; payer spend: ~$45–55M\/year\u003c\/li\u003e\n\u003cli\u003eKey tasks: CLIA\/CAP compliance, FDA submissions, payer negotiations\u003c\/li\u003e\n\u003cli\u003eOutputs: data reports, health-economic dossiers, coding\/billing updates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMyriad: $1.1B diagnostics, 1.2M tests, 7-day TAT, $110M R\u0026amp;D, VUS -18% YoY\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMyriad operates CLIA\/CAP labs processing ~1.2M tests (2024) with ~7-day turnaround, \u0026gt;99.5% concordance, and VUS down 18% YoY; spends ~$110M (≈15% revenue) on R\u0026amp;D to improve assays and AI risk models; invests $45–55M\/year in regulatory, payer engagement, and coding to support $1.1B diagnostics revenue (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTests processed\u003c\/td\u003e\n\u003ctd\u003e1.2M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTurnaround\u003c\/td\u003e\n\u003ctd\u003e~7 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$110M (15% rev)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDiagnostics revenue\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/payer spend\u003c\/td\u003e\n\u003ctd\u003e$45–55M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVUS change YoY\u003c\/td\u003e\n\u003ctd\u003e-18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview you see is the actual Myriad Business Model Canvas file—not a mockup or sample—and it reflects the exact structure, content, and formatting you will receive after purchase.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56749683605881,"sku":"myriad-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/myriad-business-model-canvas.png?v=1772216920","url":"https:\/\/growthsharematrix.com\/products\/myriad-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}